Poly Medicure announced its unaudited financial results for the second quarter of FY26. Consolidated revenue grew by 5.7%, with domestic revenue up by 16.9%. The company completed acquisitions of PendraCare Group and Citieffe Group. Operating EBITDA margin stood at 26.8%. The company maintains a strong liquidity position with ₹1,109.1 Crs in net cash as of September 30, 2025.
Financial Performance
Poly Medicure reported a consolidated revenue growth of 5.7% for Q2 FY26, with domestic revenue showing a stronger growth of 16.9%. The Operating EBITDA margin for the quarter was 26.8%.
Key Highlights for Q2 FY26
- Completed acquisitions of PendraCare Group (Netherlands – Cardiology) and Citieffe Group (Italy – Orthopaedics).
- Launched “Polymed Academy of Clinical Excellence” (PACE).
- Launched 8 new products.
Consolidated Financial Results Summary
Key figures for Q2 FY26 (July-September):
- Revenue from Operations: ₹443.9 Crs (up 5.7% year-over-year)
- Gross Profit: ₹308.2 Crs (up 7.2% year-over-year)
- Operating EBITDA: ₹118.8 Crs (up 2.5% year-over-year)
- PAT: ₹91.8 Crs (up 5.0% year-over-year)
Balance Sheet Highlights
- Net Cash: ₹1,109.1 Crs as of September 30, 2025
Segment Performance
- Infusion Therapy: ₹273.5 Crs
- Renal: ₹44.2 Crs
- Others: ₹125.9 Crs
Shareholding Pattern
As of September 30, 2025:
- Promoters & Promoter Group: 62.4%
- Foreign Portfolio Investors: 9.8%
Source: BSE
